Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Northrop Grumman Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Northrop Grumman Corporation trades at $543.05 (market cap $77.98B). The key difference: Northrop Grumman Corporation is far larger — about 17.4× ACADIA Pharmaceuticals Inc.'s market cap, and Northrop Grumman Corporation pays a 1.71% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NOC | |
|---|---|---|
Market Cap | $4.49B | $77.98B |
Sector | Health | Industrials |
52-Week High | $28.06 | $768.02 |
52-Week Low | $20.06 | $496.02 |
Enterprise Value | $3.69B | $92.21B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Northrop Grumman (NOC) trades at $549.04, showing minimal daily movement. The stock exhibits a bullish technical trend, supported by strong fundamentals including a 10.8% net income margin and consistent earnings beats. Recent news highlights contract wins and positive defense sector sentiment. Analyst consensus is strongly bullish with a $694.40 price target, indicating significant upside potential from current levels.
The outlook remains positive given the company's $95.61B backlog and stable cash flow generation. Key risks include political budget uncertainty and execution challenges. With solid institutional support and improving profitability metrics, NOC presents a compelling opportunity for investors seeking defense sector exposure, though geopolitical developments require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
